DHMMF, a natural flavonoid from Resina Draconis, inhibits hepatocellular carcinoma progression via inducing apoptosis and G2/M phase arrest mediated by DNA damage-driven upregulation of p21
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DHMMF, a natural flavonoid from Resina Draconis, inhibits hepatocellular carcinoma progression via inducing apoptosis and G2/M phase arrest mediated by DNA damage-driven upregulation of p21
Authors
Keywords
-
Journal
BIOCHEMICAL PHARMACOLOGY
Volume 211, Issue -, Pages 115518
Publisher
Elsevier BV
Online
2023-03-25
DOI
10.1016/j.bcp.2023.115518
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- PLK1 inhibition-based combination therapies for cancer management
- (2021) Shengqin Su et al. Translational Oncology
- Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
- (2020) David J. Newman et al. JOURNAL OF NATURAL PRODUCTS
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- Chinese Dragon’s Blood EtOAc Extract Inhibits Liver Cancer Growth Through Downregulation of Smad3
- (2020) Xiaonan Chen et al. Frontiers in Pharmacology
- RNA sequencing: new technologies and applications in cancer research
- (2020) Mingye Hong et al. Journal of Hematology & Oncology
- p21 in Cancer Research
- (2019) Shamloo et al. Cancers
- Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma
- (2018) Ting-Ting Liu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses
- (2018) Tanggang Deng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted p21WAF1/CIP1 Activation by RNAa Inhibits Hepatocellular Carcinoma Cells
- (2018) Mika Kosaka et al. Nucleic Acid Therapeutics
- Regulating a key mitotic regulator, polo‐like kinase 1 (PLK1)
- (2018) Erica G. Colicino et al. Cytoskeleton
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Flavonoid dimers from the total phenolic extract of Chinese dragon's blood, the red resin of Dracaena cochinchinensis
- (2016) Dao-Ran Pang et al. FITOTERAPIA
- The anticancer effects of Resina Draconis extract on cholangiocarcinoma
- (2016) Feng Wen et al. TUMOR BIOLOGY
- Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis
- (2015) Zhongdong Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting DNA damage response in cancer therapy
- (2014) Noriko Hosoya et al. CANCER SCIENCE
- DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
- (2013) Kahlin Cheung-Ong et al. CHEMISTRY & BIOLOGY
- p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury
- (2013) Silke Marhenke et al. GUT
- DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions
- (2013) A. Insinga et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started